Iustina Mihaela Pintilie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Iustina Mihaela Pintilie has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Oana Aurelia Vladacenco
“Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
2 shared publications - Raluca Ioana Teleanu
“Dr. Victor Gomoiu” Clinical Children’s Hospital, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
2 shared publications - Adelina-Gabriela Niculescu
Department of Science and Engineering of Oxide Materials and Nanomaterials, Politehnica University of Bucharest, 011061 Bucharest, Romania
1 shared publication - Alexandru Mihai Grumezescu
Department of Science and Engineering of Oxide Materials and Nanomaterials, Faculty of Chemical Engineering and Biotechnologies, National University of Science and Technology POLITEHNICA Bucharest, 1-7 Gheorghe Polizu Street, 011061 Bucharest, Romania
1 shared publication - Ana Cojocaru
“Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
1 shared publication - Andreea Gabriela Bratu
Faculty of Chemical Engineering and Biotechnologies, National University of Science and Technology Politehnica Bucharest, 011061 Bucharest, Romania
1 shared publication
Latest Publications
- Open Access
- 29 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8727
Advanced Drug Delivery in Pediatric Neurology: Developmental Barriers, Nanocarrier Strategies, and Translational Challenges
Treating neurological disorders in children is particularly challenging due to the dynamic maturation of the developing brain, age-dependent pharmacokinetics, and evolving structural and functional properties of the blood–brain barrier (BBB). This review explores the latest advances in drug-delivery systems tailored for pediatric neurology, emphasizing strategies to address physiological and developmental determinants of treatment response across infancy, childhood, and adolescence. The paper begins by outlining the distinct challenges of drug delivery in children, focusing on BBB maturation, transporter expression, metabolic capacity, and neurodevelopmental vulnerability. Emerging delivery systems, such as liposomes, polymeric nanoparticles, dendrimers, micelles, gold nanoparticles, and gene- and RNA-based vectors, are further reviewed in relation to major pediatric neurological conditions. These platforms demonstrate promise in enhancing drug bioavailability, targeting specific brain regions, and minimizing systemic toxicity. This paper also covers important safety, regulatory, and ethical considerations in pediatric populations, with a focus on the need for age-appropriate design and thorough clinical validation. Concluding with emerging trends and future directions, this work serves as a comprehensive resource for advancing pediatric neurological therapeutics through state-of-the-art drug delivery technologies.
- 29 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8727
Open AccessAdvanced Drug Delivery in Pediatric Neurology: Developmental Barriers, Nanocarrier Strategies, and Translational Challenges
Treating neurological disorders in children is particularly challenging due to the dynamic maturation of the developing brain, age-dependent pharmacokinetics, and evolving structural and functional properties of the blood–brain barrier (BBB). This review explores the latest advances in drug-delivery systems tailored for pediatric neurology, emphasizing strategies to address physiological and developmental determinants of treatment response across infancy, childhood, and adolescence. The paper begins by outlining the distinct challenges of drug delivery in children, focusing on BBB maturation, transporter expression, metabolic capacity, and neurodevelopmental vulnerability. Emerging delivery systems, such as liposomes, polymeric nanoparticles, dendrimers, micelles, gold nanoparticles, and gene- and RNA-based vectors, are further reviewed in relation to major pediatric neurological conditions. These platforms demonstrate promise in enhancing drug bioavailability, targeting specific brain regions, and minimizing systemic toxicity. This paper also covers important safety, regulatory, and ethical considerations in pediatric populations, with a focus on the need for age-appropriate design and thorough clinical validation. Concluding with emerging trends and future directions, this work serves as a comprehensive resource for advancing pediatric neurological therapeutics through state-of-the-art drug delivery technologies.
- Open Access
- 16 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (4) , 1685
Early Cardiac Dysfunction in Duchenne Muscular Dystrophy: A Case Report and Literature Update
Duchenne Muscular Dystrophy (DMD) is a severe X-linked recessive disorder characterized by progressive muscle degeneration due to dystrophin deficiency. Cardiac involvement, particularly dilated cardiomyopathy, significantly impacts morbidity and mortality, typically manifesting after age 10. This case report presents a rare instance of early-onset cardiac involvement in a 3-year-old male with a confirmed deletion in exon 55 of the dystrophin gene. The patient developed dilated cardiomyopathy at 3 years and 8 months, with progressive left ventricular dysfunction despite early treatment with corticosteroids, ACE inhibitors, and beta-blockers. Genetic mechanisms and genotype–phenotype correlations related to cardiac involvement were reviewed, highlighting emerging therapies such as exon skipping, vamorolone, ifetroban, and rimeporide. Studies indicate that variants in exons 12, 14–17, 31–42, 45, and 48–49 are associated with more severe cardiac impairment. This case emphasizes the need for early, ongoing cardiac assessment and personalized treatment to address disease heterogeneity. While current DMD care standards improve survival, optimizing management through early intervention and novel therapies remains essential. Further research is needed to better understand genotype–phenotype correlations and improve cardiac outcomes for patients with DMD.
- 16 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (4) , 1685
Open AccessEarly Cardiac Dysfunction in Duchenne Muscular Dystrophy: A Case Report and Literature Update
Duchenne Muscular Dystrophy (DMD) is a severe X-linked recessive disorder characterized by progressive muscle degeneration due to dystrophin deficiency. Cardiac involvement, particularly dilated cardiomyopathy, significantly impacts morbidity and mortality, typically manifesting after age 10. This case report presents a rare instance of early-onset cardiac involvement in a 3-year-old male with a confirmed deletion in exon 55 of the dystrophin gene. The patient developed dilated cardiomyopathy at 3 years and 8 months, with progressive left ventricular dysfunction despite early treatment with corticosteroids, ACE inhibitors, and beta-blockers. Genetic mechanisms and genotype–phenotype correlations related to cardiac involvement were reviewed, highlighting emerging therapies such as exon skipping, vamorolone, ifetroban, and rimeporide. Studies indicate that variants in exons 12, 14–17, 31–42, 45, and 48–49 are associated with more severe cardiac impairment. This case emphasizes the need for early, ongoing cardiac assessment and personalized treatment to address disease heterogeneity. While current DMD care standards improve survival, optimizing management through early intervention and novel therapies remains essential. Further research is needed to better understand genotype–phenotype correlations and improve cardiac outcomes for patients with DMD.